The Korean Journal of Hematology最新文献

{"title":"Prognostic significance of gelsolin and MMP12 in Langerhans cell histiocytosis.","authors":"Jong-Jin Seo,&nbsp;Taeshik Cho,&nbsp;Sun-Young Kim,&nbsp;Ibrahim Nassour,&nbsp;Hee-Jin Kim,&nbsp;Yeon-Jung Lim,&nbsp;Kyung-Nam Koh,&nbsp;Ho-Joon Im","doi":"10.5045/kjh.2012.47.4.267","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.267","url":null,"abstract":"<p><strong>Background: </strong>Gelsolin and matrix metalloproteinase 12 (MMP12) expression has been reported in Langerhans cell histiocytosis (LCH), but the clinical significance of this expression is unknown. We investigated the associations of these proteins with clinical manifestations in patients diagnosed with LCH.</p><p><strong>Methods: </strong>We performed a retrospective analysis of clinical data from patients diagnosed with LCH and followed up between 1998 and 2008. Available formalin-fixed, paraffin-embedded specimens were used for gelsolin and MMP12 immunohistochemical staining. We analyzed the expression levels of these proteins and their associations with LCH clinical features.</p><p><strong>Results: </strong>Specimens from 36 patients (20 males, 16 females) with a diagnosis of LCH based on CD1a positivity with clinical manifestations were available for immunohistochemical staining. Median patient age was 62 months (range, 5 to 207). The expression of gelsolin varied; it was high in 17 patients (47.2%), low in 11 patients (30.6%), and absent in 8 patients (22.2%). The high gelsolin expression group had a higher tendency for multi-organ and risk organ involvement, although the trend was not statistically significant. MMP12 was detected only in 7 patients (19.4%) who showed multi-system involvement (P=0.018) and lower event-free survival (P=0.002) in comparison to patients with negative MMP12 staining.</p><p><strong>Conclusion: </strong>Gelsolin and MMP12 expression may be associated with the clinical course of LCH, and MMP12 expression may be particularly associated with severe LCH. Further studies of larger populations are needed to define the precise role and significance of gelsolin and MMP12 in the pathogenesis of LCH.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"267-72"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis.","authors":"Myung-Mi Kim,&nbsp;Mi-Sun Yum,&nbsp;Hae-Won Choi,&nbsp;Tae-Sung Ko,&nbsp;Ho Joon Im,&nbsp;Jong-Jin Seo,&nbsp;Kyung-Nam Koh","doi":"10.5045/kjh.2012.47.4.273","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.273","url":null,"abstract":"<p><strong>Background: </strong>Hemophagocytic lymphohistiocytosis (HLH) is a rare multisystem disorder that frequently involves the central nervous system (CNS). We compared the clinical characteristics, treatment, and prognosis of patients with HLH according to the degree of CNS involvement.</p><p><strong>Methods: </strong>The clinical manifestations, initial laboratory data, treatment, and outcomes for 50 patients diagnosed with HLH and treated at Asan Medical Center between January 1995 and August 2011 were retrospectively reviewed and analyzed. CNS involvement was defined as the presence of neurological symptoms or an elevated white blood cell (WBC) count in the cerebrospinal fluid (CSF).</p><p><strong>Results: </strong>Among these 50 patients, 23 (46%) developed CNS disease. Among patients with CNS disease, 19 had neurological symptoms, including seizures, altered consciousness, facial palsy, dysarthria, and dysphagia. Four patients had elevated CSF WBC counts without neurological symptoms. Twelve patients had abnormal brain imaging results, including high signal intensity lesions on T2-weighted magnetic resonance imaging (MRI) findings, ventriculomegaly, hemorrhage, atrophy, and leptomeningeal enhancement. Patients with CNS disease had lower ferritin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels as well as reduced 5-year survival as compared to those without CNS disease.</p><p><strong>Conclusion: </strong>CNS involvement is common among patients with HLH. Overall, patients with CNS disease achieve poorer outcomes than patients without CNS involvement. To improve outcomes, physicians must carefully monitor the neurological manifestations in patients with HLH and administer the appropriate course of intensified chemotherapy to patients with CNS disease.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"273-80"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will JAK1/2 inhibitors change the standard of care for myelofibrosis?","authors":"Chul Won Jung","doi":"10.5045/kjh.2012.47.4.241","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.241","url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2012.47.4.241 The Korean Journal of Hematology Volume 47ᆞNumber 4ᆞDecember 2012","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"241-2"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin.","authors":"Pasquale Niscola,&nbsp;Massimiliano Palombi,&nbsp;Stefano Fratoni,&nbsp;Malgorzata Monika Trawinska,&nbsp;Laura Scaramucci,&nbsp;Andrea Tendas,&nbsp;Marco Giovannini,&nbsp;Alessio Perrotti,&nbsp;Paolo de Fabritiis","doi":"10.5045/kjh.2012.47.4.309","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.309","url":null,"abstract":"TO THE EDITOR: Gelatinous bone marrow transformation (GMT) is a rare bone marrow (BM) disorder of unknown pathogenesis. It is characterized by fat cell atrophy, focal loss of hematopoietic cells, and deposition of extracellular gelatinous substances (mucopolysaccharides rich in hyaluronic acid) [1]. The pathogenesis of GMT involves the deposition of hyaluronic acid, which hampers hematopoiesis by altering the BM microenvironment and stroma and disruption of the interactions between BM cells and cell signaling molecules [1]. GMT has been reported in association with chronic debilitating diseases, such as anorexia nervosa, malnutrition, and human immunodeficiency virus (HIV) infection, and after cytotoxic treatments [2]; in addition, GMT has been described in patients with myelodysplastic syndrome [3], acute myeloblastic leukemia [3], and idiopathic myelofibrosis [4]. However, idiopathic GMT has also been reported [5]. Herein, we report a case of idiopathic GMT in a patient who had an unusual clinical course and long-term survival. The patient was a 64-year-old Caribbean woman who had been living in Rome for more than 30 years. She was referred to our clinic in December 2005 because of anemia. Her past medical history was unremarkable. She did not use alcohol, drugs, or tobacco, and her nutritional status was excellent. Physical examination was unremarkable with the exception of pallor; the patient did not have either spleen or liver enlargement. A complete blood count at admission showed normochromic-normocytic anemia with reticulocytopenia and normal white blood cell and platelet counts. Total and unconjugated bilirubin and serum haptoglobin levels were normal. Direct and indirect indirect Coombs tests were negative. Serological tests for HIV, cytomegalovirus, Epstein-Barr virus, parvovirus B19, and hepatitis B and C viruses were negative. In addition, serum levels of tri-iodothyronine were normal. Moreover, no clinical or laboratory features of autoimmune disease were detected. Examination of peripheral blood smears revealed normal RBC; erythrocyte fragments were not detectable. Radiological examinations, which included a whole-body computed tomography scan, revealed no abnormalities. Occult blood loss was ruled out by fecal and urine analyses. A BM aspirate performed at admission resulted in a dry tap. Therefore, a BM trephine biopsy was taken. Histological examination of the BM sample revealed GMT (Fig. 1). The patient did not respond to any potentially disease-modifying treatment, including erythropoietin, prednisone, and cyclosporine. Therefore, she was managed with supportive measures, primarily transfusions. The clinical course was uncomplicated and her hematological status has remained stable. To date, 80 months after the diagnosis, she is managed only with supportive measures, consisting of 2 units of packed RBC every 3 weeks, along with iron chelation therapy. In addition, her BM features, which have been evaluated annually by BM trephi","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"309-10"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31161742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.","authors":"Tae-Dong Jeong,&nbsp;Chan-Jeoung Park,&nbsp;Hyoeun Shim,&nbsp;Seongsoo Jang,&nbsp;Hyun-Sook Chi,&nbsp;Dok Hyun Yoon,&nbsp;Dae-Young Kim,&nbsp;Jung-Hee Lee,&nbsp;Je-Hwan Lee,&nbsp;Cheolwon Suh,&nbsp;Kyoo Hyung Lee","doi":"10.5045/kjh.2012.47.4.260","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.260","url":null,"abstract":"<p><strong>Background: </strong>Flow cytometric immunophenotyping has been used to identify neoplastic plasma cell populations in patients with multiple myeloma (MM). Previous reports have described the use of several antigens, including CD38, CD138, CD56, CD117, CD52, CD19 and CD45, to distinguish distinct populations of plasma cells. The aim of this study was to evaluate a simplified immunophenotyping panel for MM analysis.</p><p><strong>Methods: </strong>A total of 70 patients were enrolled in the study, 62 of which were newly diagnosed with MM (untreated), whereas the remaining 8 were undergoing bone marrow assessment as part of follow-up after treatment (treated). Treated cases included 3 patients with relapse and 5 patients with persistence of MM. Multiparametric flow cytometric immunophenotyping was performed using monoclonal antibodies against CD56, CD19, CD138 (CD38), and CD45.</p><p><strong>Results: </strong>In differential counts, plasma cells in bone marrow (BM) accounted for 3.6-93.2% of the total nucleated cell count. The positive expression rates of CD56, CD19, CD138, and CD45 in neoplastic myeloma cells were 83.9%, 0%, 98.4%, and 37.1%, respectively, among the 62 untreated cases, and 75.0%, 0%, 87.5%, and 37.5%, respectively, among the 8 treated cases. CD19 expression of neoplastic plasma cells was negative in both untreated and treated cases.</p><p><strong>Conclusion: </strong>The simplified immunophenotyping panel, CD56/CD19/CD138(CD38)/CD45, is useful for distinguishing neoplastic myeloma cells from reactive plasma cells in clinical practice. In addition, CD19 represents the most valuable antigen for identifying neoplastic myeloma cells in patients with MM.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"260-6"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications following an unnecessary peri-operative plasma transfusion and literature review.","authors":"Jay S Raval,&nbsp;Jonathan H Waters,&nbsp;Darrell J Triulzi,&nbsp;Mark H Yazer","doi":"10.5045/kjh.2012.47.4.298","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.4.298","url":null,"abstract":"<p><p>Plasma is used to correct coagulopathies, but not all coagulation abnormalities are clinically significant enough to require correction before an invasive procedure. We report an 82 year old female who, in response to a mildly prolonged INR of unknown etiology, was unnecessarily transfused with plasma in advance of elective surgery. The patient suffered a moderately severe transfusion reaction, including hives and voice hoarseness, which caused a 4-week delay in her surgery. This delay and adverse reaction could have been avoided had the principles of evidence based plasma therapy, which we herein review, been followed and if the etiology of the mildly elevated INR been investigated before the day of her surgery.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"298-301"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of oral iron chelator deferasirox on human malignant lymphoma cells.","authors":"Jong Gwon Choi,&nbsp;Jung-Lim Kim,&nbsp;Joohee Park,&nbsp;Soonwook Lee,&nbsp;Seh Jong Park,&nbsp;Jun Suk Kim,&nbsp;Chul Won Choi","doi":"10.5045/kjh.2012.47.3.194","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.3.194","url":null,"abstract":"<p><strong>Background: </strong>Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines.</p><p><strong>Methods: </strong>Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 µM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay.</p><p><strong>Results: </strong>The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups.</p><p><strong>Conclusion: </strong>We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 3","pages":"194-201"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.3.194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30981952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?","authors":"Seok Jin Kim,&nbsp;Yong Park,&nbsp;Byung Soo Kim,&nbsp;Insun Kim,&nbsp;Young Hye Ko,&nbsp;Won Seog Kim","doi":"10.5045/kjh.2012.47.3.202","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.3.202","url":null,"abstract":"<p><strong>Background: </strong>Extranodal natural killer (NK)/T-cell lymphoma is a subtype of lymphoma that is derived from NK cells. It is considered as an aggressive form of non-Hodgkin's lymphoma because of frequent relapses and resistance to treatment. Relapsed NK/T-cell lymphoma often follows a fulminant course that is refractory to conventional chemotherapy treatment.</p><p><strong>Methods: </strong>Several patients with extranodal NK/T-cell lymphoma showed long-term survival in spite of frequent relapses. Thus, the medical records of patients diagnosed with extranodal NK/T-cell lymphoma from 1995 to 2007 were reviewed and assessed.</p><p><strong>Results: </strong>Of the 140 cases reviewed, 6 were selected (4.29%). Each of these patients had a minimum of 3 relapses or disease progression during the follow-up period, and their median overall survival was 66 months (range, 42-89 months). They were grouped according to the atypical clinical behavior observed: (1) repeated relapses or progression (≥3 times) during follow-up; and (2) long-term survival of more than 40 months, as the longest overall survival median was previously considered at approximately 40 months. The clinicopathological and laboratory characteristics of these patients were similar to those of other extranodal NK/T-cell lymphoma patients. However, 5 of the studied cases involved relatively lower expression of the proliferation-related antigen Ki-67 (<40-50%), indicating less proliferative activity. Clinically, they showed delayed relapse for at least 20 months after the initial complete remission.</p><p><strong>Conclusion: </strong>Our observations suggest that the clinical behavior of some extranodal NK/T-cell lymphoma patients differs from the typical clinical course.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 3","pages":"202-6"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.3.202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30981953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic relevance of pericardial effusion in patients with malignant diseases.","authors":"Tae-Dong Jeong,&nbsp;Seongsoo Jang,&nbsp;Chan-Jeoung Park,&nbsp;Hyun-Sook Chi","doi":"10.5045/kjh.2012.47.3.237","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.3.237","url":null,"abstract":"TO THE EDITOR: Malignancy is a common cause of pericardial effusion, and malignant pericardial effusion is a serious manifestation in advanced malignancies [1]. Malignancy-related pericardial effusion is associated with significantly decreased patient survival [1]. Slight malignant pericardial effusions are frequently asymptomatic; however, symptomatic patients often present with cardiac tamponade, which can rapidly lead to cardiovascular collapse or death [2]. Therefore, early diagnosis and timely treatment may decrease a patient's short-term risk of death. We evaluated both the etiology and prognosis of pericardial involvement in several malignancies. \u0000 \u0000We retrospectively reviewed the records of 215 patients (126 males and 89 females) with pericardial effusion and malignant diseases, including solid tumors and hematological malignancies, from January 1991 to December 2010. In all cases, the clinical diagnosis was confirmed by pathological examination of the primary tumor site. All patients underwent pericardiocentesis, and pericardial fluid analyses were performed for cytology. We analyzed the incidence of the etiology of malignancies and overall survival according to the results of the pericardial fluid analysis. Overall survival was calculated from the day of initial diagnosis to the date of patient's death from any other cause or to the latest follow-up date. \u0000 \u0000Among 215 patients, 113 (52.6%) showed pericardial involvement in their malignant diseases. The etiological diagnosis and pericardial fluid analysis results are summarized in Table 1. Pericardial involvement of malignancy was most frequent in breast carcinoma (85.0%), followed by lung adenocarcinoma (61.9%), gastric adenocarcinoma (58.8%), thymic carcinoma (33.3%), and esophageal squamous cell carcinoma (17.6%). In a survival analysis using the Cox proportional hazards model, the pericardial involvement group showed significantly poorer survival rates than the non-pericardial involvement group (hazard ratio, 2.157; 95% confidence interval, 1.327-3.507; P=0.002). The median survival time was significantly longer in patients with no evidence of pericardial involvement in their malignant diseases than in those with pericardial involvement in malignancy (118.2 months vs. 34.8 months; P=0.001) (Fig. 1). \u0000 \u0000 \u0000 \u0000Fig. 1 \u0000 \u0000Overall survival according to pericardial involvement in the malignant disease. The pericardial involvement group had a significantly poorer survival rate than the non-pericardial involvement group (Pa, pericardial involvement group vs. non-pericardial ... \u0000 \u0000 \u0000 \u0000 \u0000 \u0000Table 1 \u0000 \u0000Etiological diagnosis and frequency of pericardial involvement in malignant diseases. \u0000 \u0000 \u0000 \u0000In studies, the most common cause of malignant pericardial effusion was lung cancer (34-76%), followed by breast cancer (10-17%) [1, 3, 4]. However, in the present study, ductal cell carcinoma of the breast had the highest incidence of pericardial involvement. Because our study population included only pati","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 3","pages":"237-8"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.3.237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30981248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells.","authors":"Soo-Jeong Kim,&nbsp;Ji Eun Jang,&nbsp;June-Won Cheong,&nbsp;Ju-In Eom,&nbsp;Hoi-Kyung Jeung,&nbsp;Yundeok Kim,&nbsp;Doh Yu Hwang,&nbsp;Yoo Hong Min","doi":"10.5045/kjh.2012.47.3.178","DOIUrl":"https://doi.org/10.5045/kjh.2012.47.3.178","url":null,"abstract":"<p><strong>Background: </strong>The overexpression of Aurora A kinase (AurA) has been reported in various malignancies, including acute myeloid leukemia (AML). However, the expression of AurA and the effects of AurA inhibition in cancer stem cells are not yet fully understood. We investigated the expression and inhibition of AurA in AML stem cells (CD34(+)/CD38(-)).</p><p><strong>Methods: </strong>Expression of AurA was investigated in cell lines (NB4 and KG1) that express high levels of CD34 and low levels of CD38. Primary AML cells were harvested from 8 patients. The expression of AurA and cell death induced by inhibition of AurA were analyzed in CD34(+)/CD38(-) cells.</p><p><strong>Results: </strong>AurA was shown to be overexpressed in both primary AML cells and leukemia stem cells (LSCs) compared to normal hematopoietic stem cells. Inhibition of AurA plus cytarabine treatment in LSCs resulted in increased cytotoxicity compared to cytarabine treatment alone. Additional stimulation with granulocyte-colony stimulating factor (G-CSF) increased the cell death caused by AurA inhibition plus cytarabine treatment.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first report describing increased expression of AurA in LSCs. Our results suggest that selective AurA inhibition may be used to reduce LSCs, and this reduction may be enhanced by stimulation with G-CSF. Further exploration of relationship between nuclear factor kappa-B and AurA inhibition and the potential of AurA inhibition for use in leukemia treatment is needed.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 3","pages":"178-85"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.3.178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30981950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}